FibroGen, Inc. (LON:0IL8)

Market Cap	24.28M
Revenue (ttm)	23.66M
Net Income (ttm)	-38.00M
Shares Out	n/a
EPS (ttm)	-0.38
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3
Average Volume	10,377
Open	0.2812
Previous Close	0.2876
Day's Range	0.2812 - 0.2812
52-Week Range	0.2812 - 20.8000
Beta	n/a
RSI	48.03
Earnings Date	May 5, 2025

About FibroGen

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 a...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1993
• Employees: 225
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0IL8

Financial Performance

In 2024, FibroGen's revenue was $29.62 million, a decrease of -36.71% compared to the previous year's $46.80 million. Losses were -$47.58 million, -83.26% less than in 2023.

Financial numbers in USD